Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum: Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

  • 1,
  • 1,
  • 1 and
  • 1Email author
Diabetology & Metabolic Syndrome20157:61

https://doi.org/10.1186/s13098-015-0056-x

  • Received: 24 February 2015
  • Accepted: 18 June 2015
  • Published:

The original article was published in Diabetology & Metabolic Syndrome 2014 6:104

Erratum

After publication of this manuscript [1], we noted errors to the labels of Fig. 7. The Y-axis of panel C was incorrectly labelled as “Plasma Adiponectin, ng/ml” instead of “PEPCK, % of Vehicle”. (Please see a corrected version of Fig. 7 below).
Fig. 7
Fig. 7

Impact of timed daily bromocriptine or vehicle administration on gluconeogenic pathway regulators – FOXO1 phosphorylated at Ser256 (Panel a), glucose-6-phosphatase (Panel b), and PEPCK (Panel c). Proteins we quantified by Western blotting. Values are means ± SEM of 8 animals in each group. *Difference is statistically significant; P values are noted under each panel

Notes

Authors’ Affiliations

(1)
VeroScience LLC, Tiverton, RI 02878, USA

Reference

  1. Ezrokhi M, Luo S, Trubitsyna Y, Cincotta AH. Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. Diabetol Metab Syndr. 2014;6:104.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

Advertisement